Renal Cell Carcinoma News and Research RSS Feed - Renal Cell Carcinoma News and Research

Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products.
GW researchers awarded $2.2 million NCI grant to study role of HERVs in cancer

GW researchers awarded $2.2 million NCI grant to study role of HERVs in cancer

George Washington University researchers received a $2.2 million grant from the National Cancer Institute to uncover why certain cancer types increase whereas others are unchanged or even decrease in those with HIV infection. [More]
Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab). [More]
Experimental drug outperforms standard first-line therapy for advanced kidney cancer patients

Experimental drug outperforms standard first-line therapy for advanced kidney cancer patients

An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase II clinical trial by researchers at Dana-Farber Cancer Institute. [More]
Researchers find new path to stop metastatic growth of cancer

Researchers find new path to stop metastatic growth of cancer

Investigators from the Research Institute of the McGill University Health Centre, and the Institute of Cancer Research, London, have discovered that some cancer cells can draw blood from existing mature blood vessels allowing them to continue to spread. [More]
Researchers to explore potential roles of tumor-suppressor gene in kidney cancer

Researchers to explore potential roles of tumor-suppressor gene in kidney cancer

Renal cell carcinoma is the most common type of kidney cancer, and African-Americans and males appear most at risk for this disease that can be asymptomatic until it has spread and become highly lethal, said Dr. Vinata B. Lokeshwar, cancer researcher and chair of the Department of Biochemistry and Molecular Biology at the Medical College of Georgia at Augusta University. [More]
Overweight kidney cancer patients live longer than normal-weight counterparts, study shows

Overweight kidney cancer patients live longer than normal-weight counterparts, study shows

Obesity almost always increases cancer risk and worsens outcomes, but researchers led by scientists at Dana-Farber Cancer Institute report that overweight patients with advanced kidney cancer had significantly longer survival than those who were normal or underweight. [More]
Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach means some patients could delay taking highly toxic non-curative anticancer drugs that come with substantial side effects [More]
Researchers identify potential biomarkers predictive of TKIs response in metastatic renal cancer

Researchers identify potential biomarkers predictive of TKIs response in metastatic renal cancer

A team of CNIO researchers, in collaboration with the Spanish Oncology Genitourinary Group and the University Hospitals Leuven, has discovered various potential biomarkers predictive of tyrosine kinase inhibitors (TKIs) response in metastatic renal cancer. [More]
Immunotherapy-treated cancer patients may develop rheumatic disorders

Immunotherapy-treated cancer patients may develop rheumatic disorders

Oncologists need to be aware of the potential for rheumatological diseases in patients with cancer following treatment with immune checkpoint inhibitors, say US investigators. [More]
Cytoreductive nephrectomy can extend survival of metastatic kidney cancer patients

Cytoreductive nephrectomy can extend survival of metastatic kidney cancer patients

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in ten such patients undergo the procedure, according to a new study by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital. [More]
Cabozantinib extends advanced RCC overall survival

Cabozantinib extends advanced RCC overall survival

Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus. [More]
Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. [More]
Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options. [More]
Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Only 12% of kidney cancer patients with advanced disease survive five years after their initial treatment. In a Roswell Park Cancer Institute-led study, scientists report that some patients with advanced kidney cancer who continued to receive a novel immunotherapy drug after their disease progressed saw clinical benefit. [More]
Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces positive data from a blinded proof of concept clinical study, assessing the utility of tumor cell-free DNA as a predictor of therapeutic response to immunotherapy after the first cycle of treatment in eight different types of cancer. [More]
FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Researchers at UC Davis have shown that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces renal cell carcinoma invasiveness, growth rate, and blood vessel growth when combined with the anti-cancer therapy regorafenib. The study was published in the journal Molecular Cancer Therapeutics. [More]
Study identifies genetic differences in kidney tumors of African-Americans

Study identifies genetic differences in kidney tumors of African-Americans

A University of North Carolina Lineberger Comprehensive Cancer Center-led study has identified genetic differences in tumors of African-Americans with the most common type of kidney cancer compared with whites. [More]
Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

A research team of the Comprehensive Cancer Center of MedUni Vienna and AKH Vienna was able to demonstrate that a therapy change in the area of metastasising renal cell carcinoma significantly increases the life average expectancy and clearly improves the compatibility of the therapy. [More]
Advertisement